900, Boylston St

Boston,

MA,

USA,

ZIP: 02115

Phone: +442031418700

Last year was momentous for the cell therapy field: it was the year that CAR-T therapies became CURATIVE.

This decade of success has resulted in explosive investment into the development of CAR and TCR based approaches to ensure more patients around the world can benefit from these lifesaving therapies.  

The 8th CAR-TCR Summit is returning to Boston as the industry's trusted, definitive, end-to-end forum for the global network of autologous and allogeneic cell therapy drug developers. Ensure your whole team stays ahead of the curve with unmatched industry insights shared across discovery through to commercialization.  

Across 3 conference days with 8 content tracks, and an additional 6 deep-dive workshops, bootcamp, focus day, diversity session, C-level think tank and more, 200+ CAR and TCR experts will lead you and over 1,000 peers in discussions that will accelerate your pipeline, bringing better drugs to patients faster.  

URLs:
Tickets: https://go.evvnt.com/1657045-2?pid=1052
Brochure: https://go.evvnt.com/1657045-3?pid=1052
YouTube: https://go.evvnt.com/1657045-4?pid=1052

Prices:
Drug Developer Pricing - 3 Day Conference Only: USD 4649.00,
Start Up Pricing - 3 Day Conference Only: USD 3549.00,
Standard Pricing - 3 Day Conference Only: USD 6649.00,
Drug Developer Pricing - 3-Day Conference + (Workshop Day OR Focus Day OR Bootcamp Day): USD 5999.00,
Start Up Pricing - 3-Day Conference + (Workshop Day OR Focus Day OR Bootcamp Day): USD 4449.00,
Standard Pricing - 3-Day Conference + (Workshop Day OR Focus Day OR Bootcamp Day): USD 8499.00,
Drug Developer Pricing - Bootcamp Day Only: USD 1499.00,
Start Up Pricing - Bootcamp Day Only: USD 1049.00,
Standard Pricing - Bootcamp Day Only: USD 1999.00

Speakers: Nelly Viseux, Senior Vice President, Process and Analytical Development and Clinical Manufacturing, 2seventy bio , Chris Bartiromo, Executive Director, Worldwide Value and Access Strategy, Cell Therapy, Lymphoma and Myeloma, Bristol Myers Squibb, John Rossi, Vice President, Head of Translational Medicine, CARGO Therapeutics, Laura McWright, Deputy Director, Seamless Care Models Group, Centers for Medicare and Medicaid Services, Stephan Grupp, Director, Cancer Immunotherapy and Cell Therapy, Children's Hospital of Philadelphia, Peter Marks, Director, Center for Biologics Evaluation and Research, FDA, Frank Neumann, Senior Vice President and Global Head of Clinical Developmentc, Kite, A Gilead Company, Jennifer Brogdon, Head of Cell and Gene Therapies, Immuno-Oncology and Hematology, Novartis Institutes of BioMedical Research , Gang Zeng, President and Chief Executive Officer, T-Cure Biosciences